Loading clinical trials...
Loading clinical trials...
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Conditions
Interventions
Antiandrogen Therapy
Laboratory Biomarker Analysis
+2 more
Locations
3
United States
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology
Petoskey, Michigan, United States
Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology
Petoskey, Michigan, United States
Start Date
June 1, 2015
Primary Completion Date
August 5, 2019
Completion Date
August 5, 2019
Last Updated
October 6, 2020
NCT02099864
NCT02446366
NCT02678351
NCT01787331
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions